Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H28N4O2 |
| Molecular Weight | 404.5047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NN(CC3CCCCC3)C4=CC=CC=C24
InChI
InChIKey=DMHWDSGURMXMGE-FQEVSTJZSA-N
InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1
| Molecular Formula | C24H28N4O2 |
| Molecular Weight | 404.5047 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:45:12 GMT 2023
by
admin
on
Sat Dec 16 11:45:12 GMT 2023
|
| Record UNII |
3877T06H05
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1185887-14-2
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY | |||
|
3877T06H05
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY | |||
|
APP-CHMINACA RM
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY | AB-CHMINACA (Item No. 15434) in a synthetic cannabinoid (CB) featuring a 1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (CHMINACA) base. It displays a 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 (Item No. 10900).1,2 APP-CHMINACA is a derivative of AB-CHMINACA. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications. | ||
|
PX-3
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY | PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication. The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014. Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015. | ||
|
DTXSID201009998
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY | |||
|
44206137
Created by
admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Ki
|
||
|
|
RACEMATE -> ENANTIOMER | |||
|
TARGET -> AGONIST |
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
